Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapyArticle Published on 2022-09-062022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, [키워드] addition Analysis Antigen CD8 Cell Cohort Control controls COVID-19 COVID-19 patient cytokine downregulated Effect elevated ELISA enrolled evaluated expression FGF Flow cytometry analysis Frequency function GM-CSF highest HLA-DR Hospitalized IFN-γ IL-10 IL-2 IL-6 immune Immune cell immune factor immune factors immunomodulatory effect in vivo Infection Inflammation information investigated MCP-1 modulating multiplex Multiplex assay Natutal Killer Cells NK cells not affect Peripheral blood plasma platform producing provide reached reduce remained SARS-CoV-2 significantly spike stimulated subject survival T cell T-cell therapy TNF-α treated was collected were measured Whole-blood with COVID-19 [DOI] 10.3389/fimmu.2022.984098 PMC 바로가기
Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report니볼루맙과 베페갈데스류킨으로 치료받은 흑색종 환자의 코로나19 감염 임상 경과: 증례 보고Case Reports Published on 2022-09-012022-09-12 Journal: Immunotherapy [Category] 진단, [키워드] administration available data bempegaldesleukin cancer patient Case report clinical Clinical characteristics Combination Course COVID-19 COVID-19 infection Cytokines IL-2 Immune checkpoint inhibitor immune-related pneumonitis Immunotherapy Laboratory mechanism of action Melanoma nivolumab nivolumab. outcome Patient Pneumonia treated Treatment [DOI] 10.2217/imt-2021-0331 PMC 바로가기 [Article Type] Case Reports
Acute kidney injury associated to COVID-19 leads to a strong unbalance of circulant immune mediatorsCOVID-19와 관련된 급성 신장 손상은 순환 면역 매개체의 강한 불균형으로 이어집니다Article Published on 2022-09-012022-09-12 Journal: Cytokine [Category] COVID19(2023년), MERS, SARS, 바이오마커, 진단, 치료기술, [키워드] accompanied Acute kidney injury AKI AKI patient AKI patients alteration analyzed association CCL-2 CCL-3 clinical outcomes contribute coronavirus disease COVID-19 COVID-19 patient CXCL-10 CXCL-8 Cytokines death demonstrated diabete Follow-up Frequency hospital discharge hospitalized patient IFN-γ IL-10 IL-2 IL-6 immune Immune mediators. immune response immunoassay immunopathological increased risk investigated kidney Kidney injury male moderate multiplex Patient performed Predictive ROC Curve SARS-CoV-2 viral load severe COVID-19 significantly significantly higher sustained the disease timepoint TNF-α VEGF Viral load were measured [DOI] 10.1016/j.cyto.2022.155974 PMC 바로가기 [Article Type] Article
Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral SclerosisRandomized Controlled Trial Published on 2022-08-292022-10-05 Journal: Neurology® neuroimmunology & neuroinflammation [Category] 바이오마커, 임상, [키워드] 1:1 ALS assigned autologous average baseline changed class classification clinical study Combined conducted COVID-19 pandemic Disease progression Dose escalation dose-escalation doses effective elevated enrolled Evidence extension Good group help IL-2 Inflammation injection intervals Lateral Sclerosis LDL Leukapheresis low-density marker matching placebo Open-label oxidative stress oxidized participant Patient Person Placebo Practice progression provide Randomized controlled trial Randomly RCT receive receptor Regulatory reliability Safe slow disease suppressive function T-lymphocyte therapy Treatment Treg Tregs Year [DOI] 10.1212/NXI.0000000000200019 PMC 바로가기 [Article Type] Randomized Controlled Trial
Clinical and immunological features associated to the development of a sustained immune humoral response in COVID-19 patients: Results from a cohort studyArticle Published on 2022-08-152022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, [키워드] abnormality acute infection acute respiratory syndrome anti-cellular antibodies anti-SARS-CoV-2 IgG antibodies antibody Antibody Response Antiviral baseline blood sample CD8 changes in characterized chemokine chemokines clinical cohort study coronavirus coronavirus disease COVID-19 Critical Critical disease Critical illness cytokine Cytokines defined Diagnosis evaluated feature flow cytometry Follow-up humoral humoral immune response Humoral response IgG IgGs IL-13 IL-2 IL-4 immune Immune profile immunological IP-10 key factor lymphocyte Lymphocytes lymphopenia Measures Neutrophil extracellular trap outcome Patient patients with COVID-19 positive Primary outcome Quantitative recruitment regulatory T cells Research Result SARS-CoV-2 serum serum cytokine Serum level serum titer strongly related sustained T cell T cells the patient variable were assessed [DOI] 10.3389/fimmu.2022.943563 PMC 바로가기
Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapiesB 세포 고갈 요법을받는 다발성 경화증 환자에서 COVID-19 예방 접종에 대한 강력한 T 세포 활성화Article Published on 2022-08-052022-09-11 Journal: Frontiers in Immunology [Category] SARS, 바이오마커, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive Adaptive immune response Adaptive immunity analyzed anti-CD20 anti-CD20 therapy antibodies antibody production B-cell binding blocking activity BNT162b2 Cellular immune response cellular response Cohort competent Complication condition controls coronavirus COVID-19 COVID-19 vaccination depleting disease driven by form forms hACE2 healthy control humoral Humoral and cellular responses IFNγ IgG antibodies IgG antibody IL-2 immunocompromised individuals Immunotherapy implication individual individuals Infection investigation mRNA mRNA-1273 mRNA-based mRNA-based vaccine multiple sclerosis no difference Ocrelizumab Patient patients proliferation RBD receiving Receptor binding domain recognizing reduced regimen relapsing respiratory rituximab SARS-CoV-2 Seroconversion seroconversion rate severe acute respiratory syndrome Coronavirus significantly significantly higher Spike protein Strong strong T-cell susceptible T-cell T-cell activation T-cell Response therapy vaccination Vaccine design virus infection [DOI] 10.3389/fimmu.2022.926318 PMC 바로가기 [Article Type] Article
JAK inhibition as a new treatment strategy for patients with COVID-19Review article Published on 2022-08-012022-10-05 Journal: Biochemical pharmacology [Category] COVID19(2023년), SARS, 바이오마커, 신약개발, 임상, 치료법, [키워드] AAK1 ACE-2 acute respiratory syndrome adverse outcomes angiotensin-converting enzyme 2 Bacterial infection blockers caused clinical trial clinical trials Combination coronavirus coronavirus disease Corticosteroids Course COVID-19 Critical cytokine Cytokine storm Cytokines Cytokines storm develop discharge Disease progression dysregulated effective Epidemic Future GAK greater herpes zoster Host ICU admission IL-2 IL-6 IL-6 receptor immune improve clinical outcome increased risk Infection Inflammation inhibit inhibiting involved Jak JAK inhibition JAK inhibitor Jak-STAT JAK/STAT JAK/STAT signaling janus medication medications Mortality MOST new treatment strategy offer pathway Patient patients with COVID-19 pro-inflammatory cytokine raised regulate released SARS-CoV-2 severe pneumonia significantly Spread Thromboembolic events TNF-α Transcription transmembrane protein Treatment upregulated viral endocytosis virus virus infection WHO guideline [DOI] 10.1016/j.bcp.2022.115162 [Article Type] Review article
Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccinationSARS-CoV-2 비활성화 백신 접종 후 장기간 회복 중인 COVID-19 개인의 강력한 체액 및 세포 면역 반응Article Published on 2022-08-012022-09-11 Journal: Frontiers in Immunology [Category] SARS, 변종, 진단, [키워드] addition anti-S Antigen antigen-specific T cell Antigen-specific T cells B cell booster caused CD4 Cellular immune response characterized convalescent COVID-19 death demonstrated Efficacy exhibited frequencies Frequency healthy healthy individual healthy individuals Hospitalization humoral IFN-γ IgG IL-2 immune immune responses inactivated Inactivated vaccine individual infected patient Infection long-term convalescent. NAbs Neutralizing antibodies neutralizing antibody neutralizing capacity RBD IgG RBD-specific IgG recipients recovered patient recovered patients robust SARS-CoV-2 SARS-CoV-2 inactivated vaccine SARS-CoV-2 RBD SARS-CoV-2 vaccine severe disease significantly significantly higher significantly increased single dose subject T cell T cell response T cell responses T cells the vaccine TNF-α utility vaccination Vaccine vaccine-induced immune response variants variants of concern VoC VOCs wild type [DOI] 10.3389/fimmu.2022.966098 PMC 바로가기 [Article Type] Article
Transient and durable T cell reactivity after COVID-19COVID-19 이후 일시적이고 지속적인 T 세포 반응성Article Published on 2022-07-262022-09-11 Journal: Proceedings of the National Academy of Sciences of [Category] COVID19(2023년), MERS, SARS, 진단, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus analyzed Antigen antigens Cell convalescent patient Convalescent patients coronavirus correlated COVID-19 cytokine Cytokines determine Ex vivo followed by IL-12 IL-13 IL-17 IL-2 Infection interferon interferon-γ interleukin long-lasting Longevity median N-terminal nucleocapsid protein Patient peptide peptides Polarity Protein reactivity remained respiratory retrieved SARS-CoV-2 severe acute respiratory syndrome Coronavirus stimulated synchronous T cell T cell cytokines T cell memory T helper T helper cells Transient triggered whole blood sample [DOI] 10.1073/pnas.2203659119 PMC 바로가기 [Article Type] Article
Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity1년 동안 SARS-CoV-2-특이적 T 세포 사이토카인 생성 반응에 대한 종단 평가는 질병 중증도와 관련된 더 큰 면역과 함께 다중 사이토카인 증식 반응의 지속성을 보여줍니다Article Published on 2022-07-132022-09-11 Journal: Journal of Virology [Category] COVID19(2023년), SARS, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 all subjects assessment average CD4 CD8 Cell Cell-mediated immunity clone coronavirus Coronaviruses Critical cytokine cytokine response Cytokines declined demonstrated dominant ELISPOT ELISpot assay envelope enzyme-linked immunosorbent epitope Epitopes Ex vivo female Frequency gamma interferon granzyme B greater GzmB highlight IFN-γ IL-2 immune immune modeling. Immunity immunodominant immunodominant epitope immunodominant epitopes induce Infection interferon interleukin interleukin 2 kill longitudinal male median membrane nucleocapsid observation other coronaviruses peaked persistence post-symptom onset potent predicted produced producing proliferative PSO reduced regions response robust SARS-CoV-1 SARS-CoV-2 seasonal coronavirus seasonal coronaviruses severe acute respiratory syndrome Coronavirus severe disease structural protein structural proteins subject survivor T cell T cell immunity T cell memory T cell response T cell responses T cells target cells Vaccine viral infections Year [DOI] 10.1128/jvi.00509-22 PMC 바로가기 [Article Type] Article